These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
481 related items for PubMed ID: 12510800
1. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA. J Bone Miner Res; 2003 Jan; 18(1):9-17. PubMed ID: 12510800 [Abstract] [Full Text] [Related]
2. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. Brixen KT, Christensen PM, Ejersted C, Langdahl BL. Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497 [Abstract] [Full Text] [Related]
3. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. N Engl J Med; 2001 May 10; 344(19):1434-41. PubMed ID: 11346808 [Abstract] [Full Text] [Related]
4. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. Marcus R, Wang O, Satterwhite J, Mitlak B. J Bone Miner Res; 2003 Jan 10; 18(1):18-23. PubMed ID: 12510801 [Abstract] [Full Text] [Related]
5. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience. Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U. J Assoc Physicians India; 2008 Jun 10; 56():418-24. PubMed ID: 18822620 [Abstract] [Full Text] [Related]
6. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH. J Bone Miner Res; 2005 Nov 10; 20(11):1905-11. PubMed ID: 16234962 [Abstract] [Full Text] [Related]
7. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL. J Bone Miner Res; 2003 Mar 10; 18(3):539-43. PubMed ID: 12619939 [Abstract] [Full Text] [Related]
8. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R. Bone; 2006 Dec 10; 39(6):1268-75. PubMed ID: 16884968 [Abstract] [Full Text] [Related]
10. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB. J Bone Miner Res; 2005 Jun 10; 20(6):962-70. PubMed ID: 15883636 [Abstract] [Full Text] [Related]
11. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide. Anastasilakis AD, Polyzos SA, Avramidis A, Papatheodorou A, Terpos E. Horm Metab Res; 2009 Jul 10; 41(7):559-62. PubMed ID: 19204890 [Abstract] [Full Text] [Related]
12. Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic. Stroup JS, Rivers SM, Abu-Baker AM, Kane MP. Pharmacotherapy; 2007 Jun 10; 27(6):779-88. PubMed ID: 17542760 [Abstract] [Full Text] [Related]
13. [Effects of teriparatide and alendronate on bone mineral density of osteoporotic rats]. Li M, Jiao J, Meng XW, Xing XP, Xia WB, Zhou XY, Liu HC, Jiang Y, Wang O, Hu YY, Zhan ZW. Zhonghua Yi Xue Za Zhi; 2005 Feb 02; 85(5):335-8. PubMed ID: 15854512 [Abstract] [Full Text] [Related]
15. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH. J Bone Miner Res; 2005 Sep 02; 20(9):1507-13. PubMed ID: 16059622 [Abstract] [Full Text] [Related]
16. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH. Arch Intern Med; 2004 Oct 11; 164(18):2024-30. PubMed ID: 15477438 [Abstract] [Full Text] [Related]
17. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. Adachi JD, Hanley DA, Lorraine JK, Yu M. Clin Ther; 2007 Sep 11; 29(9):2055-67. PubMed ID: 18035204 [Abstract] [Full Text] [Related]
18. Teriparatide for severe osteoporosis. Cappuzzo KA, Delafuente JC. Ann Pharmacother; 2004 Feb 11; 38(2):294-302. PubMed ID: 14742769 [Abstract] [Full Text] [Related]
19. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid. Prescrire Int; 2005 Feb 11; 14(75):5-9. PubMed ID: 15747448 [Abstract] [Full Text] [Related]
20. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. J Bone Miner Res; 2000 May 11; 15(5):944-51. PubMed ID: 10804025 [Abstract] [Full Text] [Related] Page: [Next] [New Search]